Please login to the form below

Not currently logged in
Email:
Password:

MHRA outlines two-year delivery plan with ‘patient first’ focus

New delivery plan also outlines strategy for UK regulatory body following Brexit

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revealed its new delivery plan, outlining its two-year strategy after departing from the European regulatory system.

The delivery plan, spanning 2021-2023, is aiming to ‘put patients first’ after the Independent Medicines and Medical Devices Safety review revealed a ‘failure to listen to and respond to patients’.

The regulator is also planning to address the challenge of strengthening international regulatory relationships now that the UK is no longer a part of the EU.

The MHRA plans to do this by evolving its regulatory framework with the goal of keeping up with life sciences developments including novel personalised medicines and software and artificial intelligence.

Although the MHRA usually publishes a corporate plan every five years, the regulatory body said that it intends to deliver the ‘more focused’ plan within a shorter time frame.

The streamlined delivery plan outlines 14 objectives that fall into six ‘central themes’ – scientific innovation, healthcare access, patient safety, dynamic organisation, collaborative partnerships and financial stability.

The delivery of these plans is underpinned by the creation of a new business model that will provide a ‘financially sustainable future’ for the MHRA.

According to the MHRA, this new model will meet the expectations of patients, healthcare professionals, the pharma industry, government and wider industry and non-profit stakeholders.

“Our response to the COVID-19 pandemic is proof positive that we can rise to challenges with fresh thinking and innovative approaches – fulfilling our responsibilities to patients first and foremost, as outlined in the Independent Medicines and Medical Devices Safety Review, and opening up the many opportunities now that the UK has left the EU, with real benefit to the brilliant UK life sciences industry and to healthcare,” said June Raine, chief executive of the MHRA.

“This plan is our response to these challenges and more. We have shown that we can not only excel under pressure and in exceptional circumstances, but also where we can take direct action to support and protect patients and improve health outcomes,” she added.

Article by
Lucy Parsons

6th July 2021

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...